Navellier & Associates Inc. Takes Position in IDEXX Laboratories, Inc. $IDXX

Navellier & Associates Inc. acquired a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 7,795 shares of the company’s stock, valued at approximately $5,274,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Swedbank AB boosted its stake in shares of IDEXX Laboratories by 0.3% during the fourth quarter. Swedbank AB now owns 37,962 shares of the company’s stock valued at $25,682,000 after purchasing an additional 130 shares in the last quarter. QRG Capital Management Inc. boosted its stake in shares of IDEXX Laboratories by 29.3% during the fourth quarter. QRG Capital Management Inc. now owns 2,496 shares of the company’s stock valued at $1,688,000 after purchasing an additional 566 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $214,000. Mcdonald Partners LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $210,000. Finally, PKO Investment Management Joint Stock Co boosted its stake in shares of IDEXX Laboratories by 19.2% during the fourth quarter. PKO Investment Management Joint Stock Co now owns 3,100 shares of the company’s stock valued at $2,097,000 after purchasing an additional 500 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Trending Headlines about IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q1 results beat expectations: EPS of $3.47 topped consensus and revenue of $1.141B was above estimates; revenue grew ~14% year-over-year and margins improved — a clear operational beat. Read More.
• Positive Sentiment: Management lifted FY‑2026 guidance to an EPS range of $14.45–$14.90 and raised the revenue range to $4.7–$4.8B, reinforcing forward growth expectations and prompting a positive market reaction. Read More.
• Positive Sentiment: Analyst commentary highlights diagnostics growth and margin expansion — several outlets flagged the beat + upgraded tone, supporting near‑term upside sentiment. Read More.
• Neutral Sentiment: The full earnings call transcript and slide deck are available for deeper diligence; these provide detail on geographic/segment trends and capital allocation but are informational rather than market-moving by themselves. Read More.
• Neutral Sentiment: The company’s published earnings presentation offers line‑item detail on organic growth drivers (Companion Animal Group, diagnostics adoption, product launches). Useful for modeling revenue cadence. Read More.
• Negative Sentiment: Valuation and near‑term upside considerations: IDXX trades at a rich multiple (P/E ~43, PEG ~3.4) after an extended one‑year rally; some commentators question whether the stock has priced in much of the good news. Technicals also show the stock below its 200‑day average, suggesting mixed momentum. Read More.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on IDXX. Weiss Ratings reiterated a “hold (c+)” rating on shares of IDEXX Laboratories in a research note on Monday, April 27th. Piper Sandler dropped their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Citigroup began coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Finally, Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $751.00.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 5,371 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the sale, the executive vice president directly owned 12,693 shares in the company, valued at $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP George Fennell sold 11,345 shares of the firm’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 45,957 shares of company stock valued at $29,862,109 over the last quarter. Insiders own 0.79% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $562.97 on Wednesday. The company has a market cap of $44.72 billion, a price-to-earnings ratio of 43.07, a price-to-earnings-growth ratio of 3.42 and a beta of 1.58. IDEXX Laboratories, Inc. has a twelve month low of $465.00 and a twelve month high of $769.98. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The company has a 50 day moving average of $588.09 and a two-hundred day moving average of $650.80.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. During the same period last year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, analysts predict that IDEXX Laboratories, Inc. will post 14.54 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.